6th IAS Conference On HIV Pathogenesis, Treatment and Prevention

Preventive and Therapeutic HIV Vaccines: Novel Candidates and Strategies in 2011 TUSY01

Symposium Back
Venue: SR 2
Time: 11:00 - 12:30, 19.07.2011
Code: TUSY01
Chairs: Barbara Ensoli, Italy
Yiming Shao, China

The session is designed to provide a general introduction for those not in the field, with an updated overview on the status of HIV vaccines in terms of outcome of recent preventive and therapeutic trials as well as new concepts being developed and tested, including clinical trial design, new vaccine candidates and delivery systems. Therapeutic vaccination as an approach to intensify, simplify or interrupt HAART therapy, as well as to contribute to HIV eradication will be discussed. Results from recent selected preventative and therapeutic approaches, which appear particularly stimulating and promising, will be presented. The session is designed to favour the interaction and discussion on the different strategies, including a comparison of the rationale behind the preventive and therapeutic approaches and what they can learn from each other to advance the field.

Presentations in this session:


Slides with audio
Preventative and therapeutic HIV vaccines: where we stand now and what we foresee
Presented by Barbara Ensoli, Italy

Slides with audio
Env-based vaccines
Presented by Susan B. Zolla-Pazner, United States

Antibody-mediated vaccines protection against HIV: the critical path to next phase of proof of concept HIV vaccine trials
Presented by Susan Barnett, United States

DNA vaccines
Presented by David Weiner, United States

Slides with audio
Dendritic cell-based therapeutic vaccine approaches
Presented by Felipe Garcia, Spain

Questions and answers


Powerpoints presentations
Preventative and therapeutic HIV vaccines: where we stand now and what we foresee - Barbara Ensoli

Env-based vaccines - Susan B. Zolla-Pazner

Dendritic cell-based therapeutic vaccine approaches - Felipe Garcia

Rapporteur reports

Community Advisory Group report by Simone Marcotullio

Barbara Ensoli from the National AIDS Centre in Rome, gave a comprehensive lecture on “Where we are in both vaccine fields: therapeutic and preventive”.

Preventive vaccines: Out of 42 candidates, only 8 are being tested in multiple phases and 2 in phase IIB. Interesting of note her approach on Tat-Delta V2 Env complex: a multicentric phase I open-label trial started one month ago with in 50 high risk individuals in Italy in cooperation with Novartis.

Therapeutic vaccines: 6 candidates are in early phases; Tat Italian strategy is the most advanced (phase II). Therapeutic approaches are important for sustaining and integrating ARVs for PLWHA.



Track A report by Scott G. Kitchen

The session TUSY01Preventative and Therapeutic HIV Vaccines: Novel Candidates and Strategies in 2011” highlighted some recent advances in HIV vaccine- related issues in the context of historical perspective. Overall, discussion highlighted the three major, recent vaccine trials: the AIDSVAX, STEP, and ALVAC/AIDSVAX trials and ways that the field is moving on from these studies, learning from both success and failures. Discussion also highlighted the need and importance for the generation of humoral and cellular immunity in an approach for a successful vaccine.  
 Dr. Barbara Ensoli began the discussion as co-chair of the session with a historical perspective/overview and highlighted the fact that there are currently 42 unique vaccine candidates under clinical development, none beyond Phase IIb. There are several promising preventative and therapeutic candidates in the pipeline that were discussed; and she highlighted her own recent work in the utilization of a vaccine involving a combination of HIV Tat and Env being efficacious in protecting macaques from mucosal SHIV challenge. 
Dr. Susan Zolla-Pazner then discussed her work in the development of a “Structural Vaccinology Approach”, which involves the rational design of immunogens that can focus the immune response, particularly neutralizing monoclonal antibodies, on specific epitopes of HIV. She demonstrates the success in this approach in inducing cross-clade neutralizing antibodies using a gp120 DNA-based prime followed by a boost with a Env V3 attached to a Cholera Toxin B protein scaffold immunogen.
Dr. Susan Barnet provided an overview of results from the RV144 trial and other studies utilizing non-human primates, which suggest that vaccine protection from HIV is an achievable goal. The protection seen in these studies can be attributed to the ability of the vaccine candidate to elicit high aviditiy, high titer, Env targeting neutralizing antibodies. The ongoing goal is to identify a candidate that will provide this type of protection in humans.
Dr. David Weiner discussed significant advances in the development of DNA based vaccines and has identified an “enhanced” DNA vaccine candidate. When the DNA containing consensus sequences of the target antigen is combined with better delivery methods, such as tissue electroporation, and an IL-12 adjuvant, the DNA vaccine is capable of eliciting robust levels of cellular immune responses in HIV naïve people. This is the first demonstration of a significant positive effect of a DNA-based vaccine in humans in eliciting immunity.
Dr. Felipe Garcia highlighted past clinical trails and recent advances in dendritic cell based vaccine strategies. He emphasized the fact that the success of dendritic cell based vaccines has and is dependent on a number of variables and that a recent trial has demonstrated the ability of a dendritic cell based vaccine to elicit HIV-specific responses and reduction in viral load in a limited number of individuals. 
In all, the session highlighted past acheivement and failures and the necessity for further development of rational HIV vaccine candidates that are capable of eliciting potent antiviral immune responses.


    The organizers reserve the right to amend the programme.

Contact Us | Site map © 2011 International AIDS Society